Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,531
  • Shares Outstanding, K 25,010
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,140 K
  • 60-Month Beta 3.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 30.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.55 +100.00%
on 12/19/19
6.02 -48.50%
on 12/31/19
+1.30 (+72.22%)
since 12/17/19
3-Month
0.46 +573.91%
on 10/22/19
6.02 -48.50%
on 12/31/19
+2.61 (+533.95%)
since 10/17/19
52-Week
0.35 +783.19%
on 10/02/19
6.02 -48.50%
on 12/31/19
+1.08 (+53.47%)
since 01/17/19

Most Recent Stories

More News
Biotech Sector's Technological Advancements Winning Major Battles in the War on Cancer

USA News Group - In the war against cancer, it appears that all hands are on deck, with contributions coming from across the biotech sector. As the 2020s begin, new approvals and promising data are encouraging...

ONCY : 3.10 (-2.52%)
ONC.TO : 4.05 (-2.41%)
GSK : 47.89 (+1.55%)
MRK : 90.97 (-0.23%)
CLVS : 9.85 (+3.96%)
AEMD : 2.06 (-25.36%)
New Study Indicates 'Helper' Cells May Kill Cancerous Tumors

USA News Group - A new study out suggests that T cells are a subset of lymphocytes (white blood cells), which play a key role in the body's immune response. This new information could prove to be a key...

ALNY : 118.82 (-0.44%)
ONCY : 3.10 (-2.52%)
ONC.TO : 4.05 (-2.41%)
BMY : 66.72 (-0.09%)
AEMD : 2.06 (-25.36%)
'Guided-Missile' Cancer Drugs are the Biotech Sector's First Major Story of the 2020s

USA News Group - With a new decade still less than a month underway, it appears the 2020s should see some major breakthroughs in the fight against cancer. A recent analysis from Reuters uncovered that...

ONCY : 3.10 (-2.52%)
ONC.TO : 4.05 (-2.41%)
RHHBY : 42.4200 (+1.60%)
SGEN : 109.00 (+1.24%)
AZN : 51.33 (+1.62%)
IMMU : 19.00 (-1.78%)
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) (TSX: ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided a recap of a Key Opinion Leader call...

ONCY : 3.10 (-2.52%)
ONC.TO : 4.05 (-2.41%)
Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a...

ONCY : 3.10 (-2.52%)
ONC.TO : 4.05 (-2.41%)
Will Oncolytics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Oncolytics.

ONCY : 3.10 (-2.52%)
Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 12, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today...

ONCY : 3.10 (-2.52%)
ONC.TO : 4.05 (-2.41%)
Cancer Drug Revenues Expected to be Largest Share in Pharma Market

One of the latest market reports in the published by Credence Research, Inc. shows that the Multiple Myeloma Treatment market, which was valued at USD $8,398.3 Mn in 2016, is expected to reach USD $21,221.8...

ONCY : 3.10 (-2.52%)
ONC.TO : 4.05 (-2.41%)
EPZM : 26.72 (+4.62%)
LXRX : 4.04 (-4.72%)
ABBV : 88.00 (-1.41%)
BMY : 66.72 (-0.09%)
Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement

Oncolytics Biotech Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it received written notice from Nasdaq stating that...

ONCY : 3.10 (-2.52%)
ONC.TO : 4.05 (-2.41%)
It's Been a Particularly Exciting Year for Biotech Stocks Across the Board

The biotech sector continues to grow as valuations are sky high, based on recent M&A's within the industry. 2019 started off with a boom with the announcement of two multi-billion-dollar deals valued at...

ONCY : 3.10 (-2.52%)
CCXI : 43.66 (+6.67%)
AKRO : 20.18 (+2.49%)
ALXN : 113.27 (+0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade ONCY with:

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

2nd Resistance Point 3.48
1st Resistance Point 3.29
Last Price 3.10
1st Support Level 2.98
2nd Support Level 2.86

See More

52-Week High 6.02
Fibonacci 61.8% 3.85
Fibonacci 50% 3.19
Last Price 3.10
Fibonacci 38.2% 2.52
52-Week Low 0.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar